About FYR Diagnostics
FYR Diagnostics is a company based in Missoula (United States) founded in 2016. FYR Diagnostics has raised $8 million across 4 funding rounds from investors including HHS and America’s Seed Fund. FYR Diagnostics offers products and services including Liquid Biopsy Solutions and Sequencing Services. FYR Diagnostics operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
- Headquarter Missoula, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8 M (USD)
in 4 rounds
-
Latest Funding Round
$8 M (USD), Series A
Aug 02, 2024
-
Investors
HHS
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of FYR Diagnostics
FYR Diagnostics offers a comprehensive portfolio of products and services, including Liquid Biopsy Solutions and Sequencing Services.
Develops tools using EVs for detecting disease biomarkers in healthcare.
Offers high-quality next-generation sequencing for clinical and research needs.
People of FYR Diagnostics
Unlock access to complete
Leadership Team
2 people
Product Management Team
2 people
Junior Team
1 people
Operations Team
1 people
Unlock access to complete
Funding Insights of FYR Diagnostics
FYR Diagnostics has successfully raised a total of $8M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $8 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in FYR Diagnostics
FYR Diagnostics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and America’s Seed Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for FYR Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by FYR Diagnostics
Investment portfolio details for FYR Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - FYR Diagnostics
Detailed financials for FYR Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fyr Diagnostics Comparisons
Peer comparison for FYR Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of FYR Diagnostics
FYR Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Novel cancer drugs are developed using synthetic lethality screening.
|
|
| Locked | Locked | Locked |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
Detailed competitors of FYR Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fyr Diagnostics
Complete news archive for FYR Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FYR Diagnostics
FYR Diagnostics was founded in 2016 and raised its 1st funding round 3 years after it was founded.
FYR Diagnostics is headquartered in Missoula, United States. It is registered at Missoula, Montana, United States.
FYR Diagnostics is a funded company, having raised a total of $8M across 4 funding rounds to date.
FYR Diagnostics was founded in 2016 in Missoula, United States, within the healthcare and diagnostics sector. In-vitro diagnostic tests are offered for disease detection in humans and agriculture. A portfolio of biomarker detection technologies is developed, emphasizing nucleic acid amplification methods. These technologies support accelerated prediction, diagnosis, and management of diseases through laboratory-based operations.
FYR Diagnostics's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
FYR Diagnostics offers Liquid Biopsy Solutions and Sequencing Services.
FYR Diagnostics has 2 investors. Key investors include HHS, and America’s Seed Fund.